PHA－LAK与常规LAK细胞生物学特性的比较

本文对来自正常人Ｏ型外周血单个核细胞（ＰＢＭＣ）,经ＰＨＡ预刺激４８小时,然后用ｒＩＬ－２诱导的ＬＡＫ细胞（ＰＨＡ－ＬＡＫ）和直接用ｒＩＬ－２诱导的常规制备的ＬＡＫ细胞的生物学特性进行了比较。结果表明ＰＨＡ－ＬＡＫ和常规ＬＡＫ在细胞形态、核型和细胞化学等方面均相似;而在增殖能力、体外存活时间、细胞毒活性方面ＰＨＡ－ＬＡＫ明显优于常规ＬＡＫ。ＦＡＣＳ表型分析表明：ＰＨＡ－ＬＡＫ的表型以ＣＤ３＋ＣＤ８＋为主,而常规ＬＡＫ则以ＣＤ３＋ＮＫＨ￣＋＿１为主,且ＰＨＡ－ＬＡＫＩＬ－２Ｒ的表达水平高于常规ＬＡＫ。采用ＰＨＡ－ＬＡＫ可较好地解决ＬＡＫ细胞的数量和活性问题,这在ＩＬ－２／ＬＡＫ疗法中有重要的实用价值。     

树突状细胞对LAK细胞抗人鼻咽癌细胞的促进作用

本研究对人血树突状细胞联合ＬＡＫ细胞和ＩＬ－２对人鼻咽癌细胞株Ｈｅｐ－２的抗肿瘤活性进行了体外观察。实验分为ＬＡＫ组，ＬＡＫ＋ＤＣ组和ＬＡＫ＋ＤＣ＋ＩＬ－２组；效靶比例分别采用１０：１和２０：１二种。３７℃，５％ＣＯ２，饱湿条件下培养４８ｈ后，用中性红摄入比色法检测细胞毒活性。     

人白细胞介素4诱导杀伤细胞的研究

人重组白细胞介素４（ｒｈＩＬ－４）在ＰＨＡ协同下，从人外周血单核细胞（ＰＢＭＣ）诱导出明显的ＬＡＫ活性，其对Ｋ５６２、Ｒａｊｉ细胞的杀伤力低于ＩＬ－２诱导者，对ＴＢＬ－Ｅ，ＰＨＡ活化的淋巴母细胞（ＰＨＡ－ｂｌａｓｔｓ）的杀伤力和ＩＬ－２诱导者相似。在ＰＨＡ介导的４小时５１Ｃｒ杀伤试验中，加入ＰＨＡ后，ＩＬ－４－ＬＡＫ对ＰＨＡ－ｂｌａｓｔｓ的杀伤力提高２．３倍，而ＩＬ－２－ＬＡＫ对ＰＨＡ－ｂｌａｓｔｓ的杀伤力无变化，提示ＩＬ－４主要诱导ＣＴＬ样活性，而ＩＬ－２主要诱导ＮＫ样活性，ＩＬ－４诱导效应ＣＴＬ的能力强于ＩＬ－２。我们的实验同时证实，在淋巴细胞活化的早期，ＩＬ－４抑制ＩＬ－２诱导的ＬＡＫ活性，淋巴细胞活化后，ＩＬ－４与ＩＬ－２有协同作用，增强ＩＬ－２诱导的ＬＡＫ活性。     

转移因子和免疫核糖核酸对LAK细胞抗肿瘤活性的影响

本研究用重组白细胞介素２（ｒＩＬ－２）联合转移因子（ＴＦ）或抗肿瘤免疫核糖核酸（ｉＲＮＡ）作用于外周血单个核细胞（ＰＢＭＣ），测定其对Ｋ５６２，Ｒａｊｉ及Ｈ７４０４细胞的杀伤活性。结果发现，高浓度ＴＦ（０．２５ｕ／ｍｌ）可抑制ＬＡＫ活性，ＴＦ进一步稀释（０．１２５ｕ／ｍｌ）可使其抑制作用消失。ＴＦ和抗肿瘤ｉＲＮＡ不能进一步提高最适剂量ｒＩＬ－２（５００ｕ／ｍｌ）诱导的ＬＡＫ活性，但能显著增强亚适剂量ｒＩＬ－２（２００ｕ／ｍｌ）诱导的ＬＡＫ活性，诱导ＬＡＫ活性增高的ＴＦ最适剂量为０．０３１ｕ／ｍｌ。ＴＦ或抗肿瘤ｉＲＮＡ单独不能诱导出ＬＡＫ活性，而当两者联合应用可诱导ＰＢＭＣ产生ＬＡＫ活性。本文为ＴＦ及抗肿瘤ｉＲＮＡ协同ＬＡＫ细胞疗法在临床应用提供实验基础。     

慢性乙型肝炎,肝硬化患者外周血LAK细胞活性和sIL—2R测定的意义

采用＾３Ｈ－ＴｄＲ释放法测定５１例慢性肝病患者（ＣＰＨ１０例、ＣＡＨ２３例、ＬＣ１８例）外周血ＬＡＫ细胞活性，并用酶联法测定患者血清中ｓＩＬ－２Ｒ含量；与２９例正常对照组比较，发现肝病患者ＬＡＫ活性降低，ＨＢＶＤＮＡ阳性组ＬＡＫ活性较阴性组低（Ｐ〈０．０５），ｓＩＬ－２Ｒ增高，且慢性肝病组ＬＡＫ活性与ｓＩＬ－２Ｒ水平呈负相关，说明ＬＡＫ活性与机体免疫功能状态有关，ＨＢＶ的复制和高浓度的ｓＩＬ－２Ｒ     

肿瘤患者自体CD3AK与LAK细胞生物学特性研究

目的：ＣＤ３ＡＫ细胞是由抗ＣＤ３单克隆抗体和ＩＬ－２共同激活诱导的肿瘤杀伤细胞。对３０例肿瘤患者自体ＤＣ３ＡＫ细胞及ＬＡＫ细胞进行了比较性研究。方法：采用ＭＴＴ法检测ＣＤ３ＡＫ细胞及ＬＡＫ细胞的杀瘤活性,应用流工细胞术进行免疫标志物分析。结果与结论：肿瘤患者ＰＢＭＮＣ诱导后产生的ＣＤ３ＡＫ细胞较ＬＡＫ细胞有更强的增殖能力,但对Ｒａｊｉ、Ｋ５６２细胞的生长抑制作用无明显区别;４０％～６０％ＣＤ３ＡＫ     

淫羊藿甙逆转转化生长因子β2对LAK,CD3AK细胞的免疫抑 …

目的 探讨淫羊藿甙逆转转化生长因子β２（Ｔｒａｎｓｆｏｒｍｉｎｇ Ｇｒｏｗｔｈ Ｆａｃｔｏｒ β２ＴＧＦβ２）对ＬＡＫ、ＣＤ３ＡＫ细胞的免疫抑制作用及其机制。方法 采用ＭＴＴ法,ＲＴ－ＰＣＲ和流式细胞术。结果 淫羊藿降转受ＴＧＦβ２抑制的ＬＡＫ和ＣＤ３ＡＫ细胞的杀伤活性,并能部分恢复受ＴＧＦβ２抑制的ＬＡＫ细胞表面ＩＬ－２Ｒα表达和ＣＤ３ＡＫ细胞内穿孔素ｍＲＮＡ水平,以及ＣＤ３ＡＫ细胞的增殖活性。     

人外周血树突状细胞在LAK抗HPBALL细胞中作用的研究

为探讨树突状细胞（ＤＣ）在ＬＡＫ抗ＨＰＢＡＬＬ细胞中的作用，采用多因素、多水平的杀伤试验，同时以光镜、电镜观察ＤＣ、ＬＡＫ、ＨＰＢＡＬＬ相互作用的形态特征及ＤＮＡ断端标记法检测瘤细胞是否凋亡。结果表明：（１）ＤＣ无直接杀伤ＨＰＢＡＬＬ作用。（２）５×１０５～１×１０７／ＬＤＣ有增强不同Ｅ／ＴＬＡＫ杀伤活性的趋势，而１×１０７～５×１０７／ＬＤＣ对ＬＡＫ活性有抑制趋势。（３）ＤＣ、ＬＡＫ杀伤ＨＰＢＡＬＬ的最佳组合条件为：ＤＣ培养４ｄ、浓度５×１０６／Ｌ，ＬＡＫＥ／Ｔ＝１０／１，ｒＩＬ－２＝０。（４）光镜、电镜下均可见ＤＣ的突起与ＬＡＫ、ＨＰＢＡＬＬ细胞紧密接触形成细胞簇。（５）ＤＮＡ断端标记法显示瘤细胞呈末端脱氧核糖核酸转移酶阳性反应。结论：ＤＣ对ＬＡＫ杀伤ＨＰＢＡＬＬ活性具有双向调节作用     

IL—2,IL—4和IL—7体外诱导人外周血淋巴因子激活的杀伤细胞效应…

比较了淋巴因子ＩＬ－２、ＩＬ－４和ＩＬ－７ 在体外诱导健康人外周血淋巴因子激活的杀伤（ＬＡＫ）细胞活性的效应。结果表明，ＩＬ－７可单独，亦可与ＩＬ－２、ＩＬ－４协同诱导ＬＡＫ细胞，而且ＩＬ－７诱导ＬＡＫ细胞的效应不被抗ＩＬ－２、抗ＩＬ－４所抑制。ＩＬ－７单独诱导的ＬＡＫ细胞活性高峰迟于ＩＬ－２或ＩＬ－４所诱导的活性高峰，且与增殖反应曲线一致。抗ＣＤ８抗体明显抑制ＩＬ－７诱导ＬＡＫ细胞的效应，而ＩＬ     

rhIL-15和rhIL-2诱生的LAK细胞特性比较

目的：研究ｒｈＩＬ－１５激活的ＬＡＫ细胞的增殖、细胞毒作用及相关表型的变化。方法：通过用不同浓度的ｒｈＩＬ－１５和ｒｈＩＬ－２分别诱生 ＬＡＫ细胞，研究二者诱生的 ＬＡＫ细胞的增殖状况；当 ｒｈＩＬ－２和 ｒｈＩＬ－１５为 １５００ Ｕ／ｍｌ时，ＭＴＴ法检测 ＬＡＫ细胞的细胞毒作用，利用流式细胞仪检测细胞表面ＣＤ分子表达情况。结果：ＬＡＫ细胞的增殖对ｒｈＩＬ－２和ｒｈＩＬ－１５均具有时间和剂量依赖性，且无明显差异；终浓度为 １５００ Ｕ／ｍｌ时，ｒｈＩＬ－１５诱生的 ＬＡＫ细胞杀伤 Ｋ５６２细胞的能力强于 ｒｈＩＬ－２诱生的 ＬＡＫ细胞，而对Ｒａｊｉ细胞的杀伤活性，ｒｈＩＬ－２诱生的ＬＡＫ细胞却明显高于 ｒｈＩＬ－１５诱生的 ＩＡＫ细胞，且二者杀伤活性均具有时间依赖性；同时ｒｈＩＬ－１５诱生的ＬＡＫ细胞的ＣＤ３－ＣＤ５６＋细胞、Ｃｄ９４＋细胞百分率均高于ｒｈＩＬ－２诱生的ＬＡＫ细胞。结论：ｒｈＩＬ－１５在体内对ＮＫ细胞功能可能具有较强的调节作用。     

Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.

It has been reported that lymphocytes from peripheral blood (PBL) cultured with interleukin-2 (IL-2) produce predominantly CD16+ lymphokine-activated killer (LAK) cells. We developed a two-step method to generate LAK cells from human PBL in long-term cultures (10-12 days) with recombinant human IL-2 (rhIL-2) and characterized the evolving LAK cell population by testing its phenotype and cytotoxic activity as a function of time. The starting PBL displayed some natural killer (NK) cytotoxicity but no LAK activity. At day 6, the cells were a mixed population of about 80% CD3+ and 6% CD16+ cells. Little proliferation was evident but strong LAK activity was detected. After 10-12 days, major cell expansion had occurred and they were essentially a pure (greater than 90%) CD3+ CD16- CD56- cell population large granular lymphocyte (LGL) by morphology that displayed strong non-MHC-restricted killing activity (greater than 200 lytic units). Over the same period of time, the CD16+ cells had almost completely regressed in these cultures. This preferential induction of CD+ LAK cells was not an effect of IL-2 concentration as 10 U/ml was as effective as 500 U/ml. Further characterization revealed a major population of CD4+ (60%) and CD8+ (30%) with a smaller fraction (less than 9%) of gamma delta + cells. These results indicate that a virtually pure CD3+ LAK cells population was produced with long-term cultures of lymphocytes from peripheral blood in rhIL-2, in which active proliferation of the CD3+ but not CD16+ cells occurred.     

PHA-LAK细胞激活培养过程中多项免疫学指标的动态分析

本文用APAAP、ELISA、MTT等方法检测了PHA—LAK细胞激活培养过程中某些免疫学指标的动态变化,结果表明:(1)在PHA-LAK细胞预刺激阶段,CD3~+、CD4~+、CD8~+及mIL-2Ra~+细胞百分率均持续升高(P均<0.01);上清液中sIL-2R水平和IL-2活性也升高,且前者与MIL-2Ra~+细胞百分率呈正相关(r=0.84,P<0.05);(2)在rIL2激活培养阶段,CD3~+、mIL-2Ra~+细胞百分率居高不下,CD4~+细胞百分率逐渐降低,而CD8~+细胞百分率则逐渐升高,培养上清液中sIL-2R水平增加和IL-2活性降低的幅度以激活培养的初期(0～3d)为最大.从而提示PBMC经预刺激后可迅速被外源性的rIL-2激活,这不仅可以提高rIL-2的利用率,也可能是PHA-LAK细胞具有较高增殖能力和细胞毒活性的原因.     

LAK、CD3AK和PHA-LAK细胞体外增殖和杀瘤活性比较

本文对LAK、CD3AK、PHA-LAK细胞的体外增殖能力、杀伤谱进行了同步比较.结果表明,三种效应细胞对悬浮和贴壁的肿瘤细胞系及新鲜分离的脑胶质瘤细胞均有较高的杀伤活性.由于LAK细胞增殖慢、IL-2用量大,PHA-LAK细胞体外存活时间短,而CD3AK细胞扩增倍数最高、细胞存活时间长、培养体系总的杀伤单位明显高于LAK和PHA-LAK细胞,且IL-2用量少.因此,我们认为CD3AK细胞是优于LAK和PHA-LAK细胞的较为安全、有效、经济的用于过继免疫治疗的抗癌效应细胞.     

Interleukin-2 induced killer cell activity against Epstein-Barr virus-immortalized human B cells

Interleukin-2 (IL-2) activated killer (LAK) cells, generated in vitro by treating peripheral blood lymphocytes (PBL) with human IL-2, are able to lyse a wide variety of target cells without restriction by major histocompatibility complex (MHC) molecules. Earlier observations from this and other laboratories indicated that patients with Epstein-Barr virus (EBV) induced infectious mononucleosis, a self-limiting viral disease, have high EBV-nonspecific natural killer (NK) cell activity. Since the effect of LAK cells on EBV-immortalized B lymphocytes has not yet been studied, we decided to investigate LAK cell activity against autologous and heterologous B lymphocytes immortralized in vitro by EBV and other EBV genome-positive and -negative targets of malignant origin. LAK activity was determined by ⁵¹Chromium release assay. The results obtained show that LAK activity was not specific for EBV and was not MHC-restricted. Results of experiments using NK cell reactive monoclonal antibodies suggest that the cytotoxicity is due predominantly to activated NK cells. Our observations suggest that LAK cells may be very effective for immunotherapy in patients with chronic or progressive EBV infections and EBV-induced lymphoproliferative diseases.     

IL-2、IL-4和IL-7体外诱导人外周血淋巴因子激活的杀伤细胞效应的比较

比较了淋巴因子ＩＬ－２、ＩＬ－４和ＩＬ－７在体外诱导健康人外周血淋巴因子激活的杀伤 （ＬＡＫ）细胞活性的效应。结果表明，ＩＬ－７可单独，亦可与ＩＬ－２、ＩＬ－４协同诱导ＬＡＫ细胞，而且ＩＬ－７ 诱导ＬＡＫ细胞的效应不被抗ＩＬ－２、抗ＩＬ－４所抑制。ＩＬ－７单独诱导的ＬＡＫ细胞活性高峰迟于ＩＬ－ ２或ＩＬ－４所诱导的活性高峰，且与增殖反应曲线一致。抗ＣＤ８抗体明显抑制ＩＬ－７诱导ＬＡＫ细胞 的效应，而ＩＬ－７诱导ＬＡＫ细胞的效应不能被抗ＮＫＨ－１所抑制。提示：ＩＬ－７ 激活ＬＡＫ细胞的效应 机制不依赖ＩＬ－２和ＩＬ－４，并很可能成为肿瘤过继治疗中的重要淋巴因子。     

In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice.

Interferon-alpha (IFN-alpha) has been shown to synergize with IL-2 in the regression of a variety of established murine tumours and studies are underway to explore this combination in patients with advanced cancers as well. To understand the mechanism of synergy we have studied lymphokine-activated killer (LAK) cell activity in various compartments of mice in response to IFN-alpha and IL-2 administration. The effects of IFN-gamma, TNF-alpha and IL-4 were also examined. C57BL/6 mice were injected intraperitoneally with HBSS, IL-2 alone, IFN-alpha alone or both, two times a day for 7 days. On days 4 and 8, LAK activity was tested in a 4-h chromium release in cells obtained from lungs, spleen, and liver using fresh MCA-102 tumour cells as targets. The cells from control mice failed to lyse the MCA-102 target. IL-2 caused the generation of LAK activity and an increase in total cell yield in all the organs after 3 days of injection. IFN-alpha failed to generate LAK activity but when administered along with IL-2, caused synergistic enhancement of LAK lysis of MCA-102 target cells. Cell yield in this group was lower as compared with the IL-2-treated group. LAK activity tested after 7 days of IL-2 therapy was significantly decreased compared with that observed after 3 days. However, activity remained at as high a level after 7 days of therapy as after 3 days of therapy in animals treated with IFN-alpha and IL-2. FACS analysis revealed that asialo GM-1+ (ASGM-1) and NK1.1+ cells were increased in number in IL-2 and IL-2 plus IFN-alpha-treated spleen; however, the number of these cells was similar in both groups. In the liver, ASGM-1+ cells were higher in the IL-2 plus IFN-alpha group than in the group treated with IL-2 alone. By in vitro depletion utilizing antibody and Rbc' experiments, it was clear that both ASGM-1+ and NK1.1+ cells from the spleen mediated most of the cytotoxicity of MCA-102 targets. Pre-treatment irradiation (5 Gy) of mice completely abrogated the capability of IL-2 or IL-2 plus IFN-alpha to generate LAK activity. IFN-gamma also had a stimulatory effect on IL-2 induction of LAK activity. Tumour necrosis factor-alpha (TNF-alpha) and IL-4 failed to generate LAK activity and, in combination with IL-2, no additional stimulatory effect was observed.(ABSTRACT TRUNCATED AT 400 WORDS)     

树突状细胞对LAK细胞抗人鼻咽癌细胞的促进作用

本研究对人血树突状细胞(Dendritic cell,DC)联合LAK(Lymphokine Activated Killer cell,LAK)细胞和IL-2对人鼻咽癌细胞株Hep-2的抗肿瘤活性进行了体外观察。实验分为LAK组、LAK+DC组和LAK+DC+IL-2组;效靶比例分别采用10:1和20:1二种。37℃、5％CO_2、饱湿条件下培养48h后,用中性红摄入比色法检测细胞毒活性。结果:各组的细胞毒活性依次为LAK+DC+IL-2组>LAK+DC组>LAK组(P<0.001),随着效靶比例升高,各组细胞毒活性增强(P<0.01).表明DC和IL-2有协同作用,能增强LAK细胞对Hep-2的细胞毒活性。     

An improved method for the generation of human lymphokine activated killer cells

In an effort to make interleukin-2/lymphokine-activated killer cell (IL-2/LAK) therapy safer for cancer patients, we examined the efficacy of using Fenwal PL732 bags as tissue culture flasks. These bags can be sterilly connected using tubing kits thus reducing the risk of contamination to the cells. Peripheral blood mononuclear cells were obtained from normal donors or cancer patients undergoing IL-2/LAK cell therapy. Following Ficoll-Hypaque purification, these cells were incubated in the presence of IL-2 in either PL732 plastic bags or standard tissue culture flasks. Our results showed that LAK cells could be generated from either normal donors or cancer patients in the bags as well as in the flasks. Comparisons were made of the LAK cell populations obtained from the two sources and showed that each was similar in terms of morphology as determined by Wright stain differentials. The populations of cells were also similar in regard to cell surface phenotype as determined by flow cytometric analysis. In addition, recoveries from either tissue culture vessel as well as cell viability of the LAK cells were comparable. Finally, the LAK cells obtained from both sources were assessed for cytolytic activity against the tumor cell lines K562 and Daudi. These results showed that the cytolytic activity of the LAK cells against these target cells was the same whether the cells were obtained from the flasks or the bags.